Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer

Inclusion Criteria: Histologically or cytologically proven NSCLC patients All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest CT and PET-CT 18 year of ages or older ECOG performance status 0-1 Uni-dimensionally measurable lesion by RECIST criteria No prior chemotherapy or radiotherapy for NSCLC Pre-operative FEV1 ≥ 2.0 L evaluated within 28 days Adequate bone marrow function: Hb > 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥ 100,000/μL Adequate liver and renal function: Total bilirubin < 2 x ULN, AST/ALT < 3 x ULN, serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min Written informed consent Exclusion Criteria: Superior sulcus tumor Prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia Recent myocardial infarction within 6 months Patients with post-obstructive pneumonia or serious infection Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method.) Patients with psychological problem